Here's what I got about that Group B; they started off sicker and they actually improved quite substantially (which is why they couldn't be differentiated from Group A significantly) but they still had CFS by Dr. Lerner's definition - which is why he called their progress 'bleak'. But I didn't think their progress was bleak at all - I thought it was pretty good. I'm not sure how he treated them differently after he got this data but apparently he did start treating them differently and he said their numbers were better than the report indicated.
From what I understand you stay on these doses until you reach at least an EIPS of 7, and then it's up to you and Dr. Lerner to determine if you'd like to ease off them. But NEVER go off either cold turkey. It throws your immune system into panic causing anything from sinusitis, bronchitis, swollen glands, thyroiditis...
However the interview with, I think, Cort, indicated that some patients recover to a 10. We also know from this thread that some patients reading this have made such a recovery.
This thread is too long for me to skim through, so my apologies if this has already been asked. Does anyone know what dosage of av's was used in the study? I've been taking valtrex for years (500mg 2x daily) with no benefit, but I am one of the more severely afflicted. I would love to increase my dose to whatever dosage Dr. Lerner used in his study.
i have read he prescribes 1000mg 4 times a day
Do you know which herpesvirus infection you have?
Well said, Cort. I think the finding is relevant to at least some readers of PR. I'm not convinced the Fukuda definition does exclude such patients and am certainly not convinced it should.You keep repeating this yet you've been shown several times that the Fukuda definition does not exclude CFS patients who have an EBV infection. Could you respond to the posts indicating that Fukuda does not exclude EBV positive patients from having CFS?
It seems to me that you're implying that the results don't apply here because they had an active infection and therefore can't be defined as having CFS. That's an amazing statement - given all the people on this Forum and elsewhere have active infections.
The critical critical question for me would be if they're results apply to me? I would guess that they very well might; that the people seeing Dr. Lerner had a mysterious fatiguing problem, had difficulties standing and exercising, etc. they had seen scads of doctors, and they finally got to Dr. Lerner.
You can parse the definition question all you want but my assumption is that people who make their way to Dr. Lerner, or Cheney or Bateman or Lapp, etc - have what I have which makes me interested in which treatments work for them.
Qualitative Holter monitor assessments
Twenty-four hour HM recordings were evaluated
qualitatively
for simple counts of abnormalities and severity, (mild, 1 point;
medium, 2 points; or severe, 3 points). Tachycardia
at rest (.100
per minute) was assessed as mild ,6 hours/24 hours;medium
.6 and 10 hours/24 hours; or severe .10 hours/24
hours). Oscillating abnormal T-wave flattenings and T-wave
inversions were evaluated as mild (occasional), medium
(intermittent), or severe (frequent) and given severity point
scores of 1, 2, or 3, respectively. Deep inverted T-waves,
multiple and multifocal ventricular premature contractions,
and bigeminal rhythms were evaluated by count and severity.
Thus, HM recordings had two numeric evaluations, ie, a
simple numeric count of types of abnormality and a severity
score. For example, a patient with an HM showing T-wave
flattening (severity score 1), mild supraventricular tachycardia
(severity score 1), but with no inverted T-waves would
equate to a severity score of 2 with an abnormality count of
2. Another patient with an HM and moderate supraventricular
tachycardia (severity score 2) “abnormal count 1”, and both
moderate numbers of oscillating T-wave flattenings (severity
score 2) “abnormal count 1”, multifocal ventricular premature
contractions (severity score 2) “abnormal count 1”, and
a bigeminal rhythm (severity
score 3) “abnormal count 1.”
The latter HM would have a total severity score of 9 and an
abnormal simple occurrence count of 4.
Baseline and follow-up serum antibody titers to EBV, HCMV, and HHV6,
as well as coinfections with Borrelia burgdorferi, Anaplasma phagocytophila, Babesia microti,
and antistreptolysin O, 24-hour ECG Holter monitors, 2D echocardiograms, cardiac dynamic
studies, symptoms, and toxicity were captured and monitored.
ECG Holter monitor recordings
Of 104 Group A CFS patients with baseline HMs and
follow-up HMs six months later, 92 (88.5%) had abnormal
baseline HM recordings.12,15 There were 77 (74%) with
abnormal oscillating T-wave flattening, 46 (44.2%) with
abnormal oscillating T-wave inversions, and 47 (44.5%) with
resting tachycardia. These abnormal HM findings in CFS
patients with no coronary artery disease, hypertension, or
abnormal electrolyte abnormalities are a biomarker of CFS
cardiomyopathy.12,15,16 Severity scores and abnormal data
counts improved with valacyclovir/valganciclovir, but did
not return to normal.
There were 25 Group B CFS patients with baseline
and repeat HMs after six months of treatment. All of these
patients had baseline abnormal HMs. Of Group B CFS
patients, 22 (88%) had abnormal oscillating T-wave flattening
and 12 patients each (48%) had abnormal oscillating
T-wave inversions and resting tachycardia.
Cardiac muscle disease, syncope, chest pain, positive tilt
table tests, tachycardias at rest, decreased left ventricular
ejection fraction, and left ventricular dilatation improved and/
or disappeared with antiviral treatment. The abnormal HM
is a reliable biomarker of CFS cardiac disease. The EIPS is
integral to follow severity and reversal of CFS illness.
Secondary endpoints of cardiac, immunologic,
and neurocognitive abnormalities improved or disappeared.
Which studies?According to Jasons studies the majority of patients diagnosed according to the Fukuda dont have the illness which has PEM as mandatory
Useful observations.Improvements in level of energy are not the same as getting back to a normal life.
I personally got to a "10" on Dr. Lerner's Energy Index quite a long time ago. But I wouldn't have suggested to anyone that I was really well until I got the cognitive component back too.
Dr. Lerner may consider improvements on the Energy Index to be a "normal life" even if patients still have other symptoms and if they still have substantial energy limitations.
I think improvements are great, but they aren't the same thing as the resolution of the illness.
Maybe I'm being too demanding, but I think the whole concept of a "functional cure" is setting our sights too low.
If people can drag themselves to some job that's a lot less challenging in every respect than the one that they could have done before they got sick, and then spend the rest of their time recovering from working, I don't think that's any sort of "cure." That's an improvement.
I bring this up because consistently, doctors/researchers use the concept of sometimes being able to effect a "functional cure" as a way to avoid looking at any factors other than the ones that they themselves already have deemed to be worthwhile.
It's not just Dr. Lerner who does this. It's the other CFS doctors too.
I'm truly happy that these doctors are finding ways to give people improvements. But until they can get people not just "Functionally Cured" but actually "Truly Well," they should keep looking for additional ways in which patients can be helped further.
It's selling us short to do otherwise.
Best, Lisa